Rapid decline of influenza vaccine-induced antibody in the elderly: Is it real, or is it relevant?

Journal of Infectious Diseases

Volumn 197, Issue 4, 2008, Pages 490-502

  Skowronski, Danuta M ^a   Tweed, S Aleina ^a,c   De Serres, Gaston ^b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE;

ANTIBODY RESPONSE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; PRIORITY JOURNAL; REVIEW; SEROCONVERSION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED;

EID: 40049108737     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/524146     Document Type: Review

References (71)

1. Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Malden MA: Blackwell Science, 1998:360.
2. Brydak LB, Machala M, Mysliwska J, Mysliwski A, Trzonkowski P. Immune response to influenza vaccination in an elderly population. J Clin Immunol 2003; 23:214-22.
3. Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15:962-7.
4. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-77.
5. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69-75.
6. Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines. 1997 March 12. CPMP/BWP/214/96 (circular 96-0666):1-22. Available at: http://www.emea.europa. eu/pdfs/human/bwp/021496en.pdf. Accessed 9 July 2007.
7. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. May 2007. Available at: http://www.fda.gov/cber/gdlns/trifluvac.htm. Accessed 9 July 2007.
8. Wood JM, Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol (Basel) 2003; 115:9-16.
9. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Oxford: Blackwell Science, 1998:219-64.
10. CDC. Tiered use of inactivated influenza vaccine in the event of a vaccine shortage. MMWR 2005; 54:749-50.
11. Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1990; 39(RR-7):1-15.
12. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-10):1-42.
13. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1994-95 season. Can Commun Dis Rep 1994; 20:85-92.
14. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2006-2007 season: An advisory Committee statement (ACS). Can Commun Dis Rep 2006; 32(ACS-7):1-27.
15. No need to worry about flu shot delay: influenza experts. Canadian Broadcasting Corporation 2006 September 26. Available at: http://www.cbc.ca/ health/story/2006/09/26/flu-shots.html. Accessed 29 October 2007.
16. Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis 1983; 5:737-47.
17. Kunzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14:1108-10.
18. McElhaney JE, Gravenstein S, Upshaw CM, Hooton JW, Krause P, Drinka P. Immune response to influenza vaccination in institutionalized elderly: effect on different T-cell subsets. Vaccine 1998; 16:403-9.
19. Gasparini R, Pozzi T, Montomoli E, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135-40.
20. Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19:308-18.
21. McElhaney JE, Hooton JW, Hooton N, Bleackley RC. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 2005; 23:3294-300.
22. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272:1661-5.
23. Cruijff M, Thijs C, Govaert T, Aretz K, Dinant GJ, Knottnerus A. The effect of smoking on influenza, influenza vaccination efficacy and on the antibody response to influenza vaccination. Vaccine 1999; 17:426-32.
24. Trzonkowski P, Mysliwska J, Godlewska B, et al. Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients. Brain Behav Immun 2004; 18:135-48.
25. Kohut ML, Arntson BA, Lee W, et al. Moderate exercise improves antibody response to influenza immunization in older adults. Vaccine 2004; 22:2298-306.
26. Kohut ML, Lee W, Martin A, et al. The exercise-induced enhancement of influenza immunity is mediated in part by improvements in psychosocial factors in older adults. Brain Behav Immun 2005; 19:357-66.
27. Powers DC, Fries LF, Murphy BR, Thumar B, Clements ML. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991; 29:498-505.
28. Powers DC, Belshe RB. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 1993; 167:584-92.
29. Powers DC. Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mech Ageing Dev 1997; 93:179-88.
30. MacKenzie JS. Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly. Br Med J 1977; 1:200-2.
31. Peters NL, Meiklejohn G, Jahnigen DW. Antibody response of an elderly population to a supplemental dose of influenza B vaccine. J Am Geriatr Soc 1988; 36:593-9.
32. Delafuente JC, Davis JA, Meuleman JR, Jones RA. Influenza vaccination and warfarin anti-coagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men. Pharmacotherapy 1998; 18:631-6.
33. Buxton JA, Skowronski DM, Ng H, et al. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis 2001; 184:188-91.
34. Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004; 32:191-8.
35. Praditsuwan R, Assantachai P, Wasi C, Puthavatana P, Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai 2005; 88:256-64.
36. Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine 2006; 24:5371-80.
37. McElhaney JE, Meneilly GS, Lechelt KE, Beattie BL, Bleackley RC. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine 1993; 11:1055-60.
38. Powers DC, Hanscome PJ, Pietrobon PJF. In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Vaccine 1995; 13:1330-5.
39. Van Hoecke C, Prikazsky V, Uto I, Menschikowski C. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 1996; 42:190-8.
40. Minutello M, Senatore F, Cecchinelli G, et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17:99-104.
41. Mysliwska J, Trzonkowski P, Szmit E, Brydak LB, Machala M, Mysliwski A. Immunomodulating effect of influenza vaccination in the elderly differing in health status. Exp Gerontol 2004; 39:1447-58.
42. Keylock KT, Lowder T, Leifheit KA, et al. Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly. J Appl Physiol 2007; 102:1090-8.
43. Roos-Van Eijndhoven DG, Cools HJ, Westendorp RG, Ten Cate-Hoek AJ, Knook DL, Remarque EJ. Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects. J Med Virol 2001; 63:293-8.
44. Gross PA, Weksler ME, Quinnan GV, et al. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987; 25:1763-5.
45. Gross PA, Quinnan GV, Weksler ME, et al. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc 1988; 36:209-12.
46. Fagiolo U, Amadori A, Cozzi E, et al. Humoral and cellular immune response to influenza virus vaccination in aged humans. Aging (Milano) 1993; 5:451-8.
47. Brandriss MW, Betts RF, Mathur U, Douglas RG. Responses of elderly subjects to monovalent A/USSR?77 (H1N1) and trivalent USSR/77(H1N1)-A/Texas/77/ (H2N2)-B/Hong Kong/72 vaccines. Am Rev Respir Dis 1981; 124:681-4.
48. Cate TR, Kasel JA, Couch RB, Six HR, Knight V. Clinical trials of bivalent influenza A/New Jersey/76-A/Victoria/75 vaccines in the elderly. J Infect Dis 1977; 136:S518-25.
49. Provinciali M, Di Stefano G, Muzzioli M, et al. Impaired antibody response to influenza vaccine in institutionalized elderly. Ann NY Acad Sci 1994; 717:307-14.
50. Beyer WEP, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7:385-94.
51. Sato M, Saito R, Tanabe N, et al. Antibody response to influenza vaccination in nursing home residents and healthcare workers during four successive seasons in Niigata, Japan. Infect Control Hosp Epidemiol 2005; 26:859-66.
52. Iorio AM, Alatri A, Camilloni B, Neri M, Baglio G, Donatelli I. Antibody response to 1995-1996 influenza vaccine in institutionalized and non-institutionalized elderly women. Gerontology 1999; 45:31-8.
53. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69.
54. Beyer WEP, Palache AM, Lüchters G, Nauta J, Osterhaus ADME. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 2004; 103:125-32.
55. Remarque EJ, deJong JMA, van der Klis RJ, Masurel N, Ligthart GJ. Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol 1999; 34:109-15.
56. Remarque EJ, de Bruijn LA, Boersma WJA, Masurel N, Ligthart GJ. Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay. J Med Virol 1998; 55:82-7.
57. Saurwein-Teissl M, Steger MM, Gluck R, Cryz S, Grubeck-Loebenstein B. Influenza vaccination in a healthy geriatric population: preferential induction of antibodies specific for the H3N2 influenza strain despite equal T cell responsiveness to all vaccine strains. Vaccine 1998; 16:196-200.
58. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21:1268-74.
59. Phyala R, Kinnunen L, Kumpulainnen V, Ikonen N, Kleemola M, Cantell K. Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift. Vaccine 1993; 11:1013-7.
60. Gravenstein S, Drinka P, Duthie EH, et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 1994; 42:245-51.
61. D'Alessio DJ, Cox PM Jr, Dick EC. Failure of inactivated influenza vaccine to protect an aged population. JAMA 1969; 210:485-9.
62. Feery BJ, Evered MG, Morrison EI. Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976. J Infect Dis 1979; 139:237-41.
63. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people: a randomized double-blind placebo-controlled trial. Vaccine 1994; 12:1185-9.
64. Paccalin M, Plouzeau C, Bouche G, et al. Lack of correlation between nutritional status and seroprotection against influenza in a long term care facility. Scand J Infect Dis 2006; 38:894-7.
65. Powers DC. Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age. J Am Geriatr Soc 1993; 41:1-5.
66. McElhaney JE, Gravenstein S, Upshaw CM, et al. Granzyme B: a marker of risk for influenza in institutionalized older adults. Vaccine 2001; 19:3744-51.
67. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Stevenson PG. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997; 159:105-17.
68. Effros RB. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 2007; 25:599-604.
69. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333-9.
70. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-16):1-54.
71. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2007-2008 season: an Advisory Committee Statement (ACS). Can Commun Dis Rep 2007; 33(ACS-8):1-38.